Related Experiment Video
Updated: Mar 23, 2026

Zika Virus Infectious Cell Culture System and the In Vitro Prophylactic Effect of Interferons
Published on: August 23, 2016
Short- and long-term effect of interferon therapy for chronic hepatitis C
1Zhen-Ya Tang, Jun-Ying Qi, Han-Xing Shen, Dong-Liang Yang, Lian-Jie Hao, Clinical Immunology Research Unit, Department of Infectious Diseases, Tongji Hospital, Tongji Medical University, Wuhan 430030, Hubei Province, China.
Aim:
To study the short and long-term effect of interferon therapy for chronic hepatitis C.
Methods:
Sixty-eight patients with chronic hepatitis C were treated with interferon (3 × 10(6) IU, im/2 d, for a course of three months) with 1 to 5 courses of treatment and followed for 1.5 to 3 years after the therapy.
Results:
According to antiviral effect of interferon, 76.5% (52/68) of the cases had a complete response by the end of the first therapy course, while 20.6% (14/68) and 2.9% (2/68) had a partial response or non-response. Over a half of the patients with a complete response (27/52, 51.9%) relapsed within 6 to 10 mo after the first course. Of the original cohort, nineteen patients received two courses of therapy, while one patient received three and another three received five courses of therapy. The follow-up for these patients was between 1.5 to 3 years, at which time 29 (42.7%) of the patients sustained a complete response, with four of them having HCV RNA positive serum, while the others had either a partial (37/68, 2.9%) or non-response.
Conclusion:
Interferon therapy had a high short-term complete response but a low long-term complete response in the treatment of chronic hepatitis C.
More Related Videos
Related Concept Videos
Inhibitors of Viral Protein Synthesis
Hepatitis
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic Pancreatitis II: Collaborative Care
Assessment:
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

